semaglutide cardiovascular outcomes 2025 news A Lancet analysis of the SELECT trial concluded that reduced major adverse events by 20% in adults with overweight or obesity, regardless of how much weight patients actually lost Cardiovascular Disease | Ozempic® (semaglutide)

Tirzepatide is marketed as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity

Since then, more than 3,300 GLP-1 stomach paralysis lawsuits have been filed in federal courts nationwide

Short-term supplementation of cinnamon has a beneficial effect on metabolism

Tirzepatide (Mounjaro/Zepbound) may cause slightly more GI side effects overall because it targets two receptors (GLP-1 + GIP), but individual responses vary

Rights and permissions About this article Cite this article Flint, A., Raben, A., Rehfeld, J

Patient safety must always take precedence over convenience